Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Relapse, followed by medication history and age, was among the highest exclusion rates for MS trials across different disease-modifying therapies.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive conversation between an expert neurologist, psychologist, patient, and care partner on various facets of multiple sclerosis.
The neurologist from Cleveland Clinic discussed how her team found that patients with AO ≤21 years old had worse visual outcomes than those >21 years old.
The director of the Massachusetts General Hospital ALS Care Center sat down to discuss "The Data is Here" campaign from Answer ALS, the world’s largest open-sourced ALS data portal.
The primary investigator of RESPOND discussed the trial’s goals and measures, as well as insight into why clinical trials like it are important in spinal muscular atrophy.